Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Aldeyra Therapeutics

Rank#9998

Market Cap82.65M

CountryUnited States

Summary

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

History

Aldeyra Therapeutics, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts. The company raised $35 million in a 2017 initial public offering and is publicly traded on the NASDAQ.

Mission

Our mission is to bring innovative therapies to patients with diseases related to free radical chemistry imbalance.

Vision

Our vision is to develop, manufacture and market products that will improve the quality of life for people suffering from these diseases.

References

https://en.wikipedia.org/wiki/Acorda_Therapeutics

https://in.investing.com/equities/aldeyra-the

https://finance.yahoo.com/quote/ALDX/profile?p=ALDX

https://www.crunchbase.com/organization/aldeyra-therapeutics

https://companiesmarketcap.com/

https://www.aldeyra.com

Leadership team

Dr. Todd C. Brady M.D., Ph.D. (CEO, Pres & Director)

Dr. Stephen G. Machatha Ph.D. (Chief Devel. Officer)

Mr. Bruce Greenberg CPA, M.B.A. (VP of Fin., Interim CFO & Treasurer)

Products / Services

Biotechnology, Developer Platform, Health Care, Therapeutics

Address

Burlington, Massachusetts, United States

Established

2004-01-01

Company Registration

SEC CIK number: 0001341235

Traded as

ALDX

Website

https://www.aldeyra.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Aldeyra Therapeutics

Rank#9998

Market Cap82.65M

CountryUnited States

Summary

History

Aldeyra Therapeutics, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts. The company raised $35 million in a 2017 initial public offering and is publicly traded on the NASDAQ.

Mission

Our mission is to bring innovative therapies to patients with diseases related to free radical chemistry imbalance.

Vision

Our vision is to develop, manufacture and market products that will improve the quality of life for people suffering from these diseases.

References

https://en.wikipedia.org/wiki/Acorda_Therapeutics

https://in.investing.com/equities/aldeyra-the

https://finance.yahoo.com/quote/ALDX/profile?p=ALDX

https://www.crunchbase.com/organization/aldeyra-therapeutics

https://companiesmarketcap.com/

https://www.aldeyra.com

Leadership team